1. 1. S. W. Lamberts, A. J. van der Lely, W. W. de Herder, and L. J. Hofland. Octreotide. N. Engl. J. Med. 334:246?254 (1996).
2. 2. E. A. Kouroumalis. Octreotide for cancer of the liver and biliary tree. Chemotherapy 47:150?161 (2001).
3. 3. D. N. Samonakis, J. Moschandreas, T. Arnaoutis, P. Skordilis, C. Leontidis, I. Vafiades, and E. Kouroumalis. Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol. Rep. 9:903?907 (2002).
4. 4. M. Raderer, M. H. Hejna, C. Muller, G. V. Kornek, A. Kurtaran, I. Virgolini, W. Fiebieger, G. Hamilton, and W. Scheithauer. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int. J. Oncol. 16:1197?1201 (2000).
5. 5. J. T. Siveke, C. Folwaczny, and C. Herberhold. Complete regression of advanced HCC with long acting octreotide. Gut 52:1531 (2003).